Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

Joseph Haas 17 Jan 2022

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Quick Listen: Scrip’s Five Must-Know Things

01 Nov 2021

In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer’s; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to Scrip.

Scrip

2020 Deal-Making Snapshot: A Busy Year For Bolt-Ons

26 Feb 2021

Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.

38th Annual J.P. Morgan Healthcare Conference Review

03 Feb 2020

The 38th Annual J.P. Morgan Healthcare Conference has concluded, and Biomedtracker and Meddevicetracker were there to bring you the important outcomes from the largest and most informative annual healthcare investment symposium in the industry.

A Life In Genes - Scrip Award Winner Sir Gregory Winters Speech

03 Oct 2018

The 2015 Scrip Lifetime Achievement Award was given to Sir Gregory Winter, Master of Trinity College, Cambridge (UK). Founder of Cambridge Antibody Technology (acquired by AstraZeneca), Domantis (acquired by GlaxoSmithKline) and Bicycle Therapeutics, he is best known for his pioneering research into humanizing antibodies. His findings led to the development of the first human antibody, Humira (adalimumab), until very recently the world's top-selling drug.

Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches

22 Aug 2018

Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.

Hong Kong Takes On Nasdaq For China Biotech IPOs

Brian Yang 09 Aug 2018

Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.

ADA Meeting's Around The Corner: Five Things To Watch For

Emily Hayes 21 Jun 2018

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

Levin Calls Takeda Shire Merger Inspired Says Entire Value Chain Must Address Pricing Issue

14 Jun 2018

Having previously criticized the biopharma industry for squandering the benefits of US tax reform, the former Teva CEO called for more M&A deals that offer a clear strategic rationale, pointing to Takeda/Shire as an example.

Arbitrating Pharma Disputes On The Rise – Planning Ahead Makes Sense

18 Jan 2018

Pharmaceutical companies risk coming up against complex and high value disputes in their everyday dealings and operations.

Datamonitor Healthcare Podcast 05 January 2018

07 Jan 2018

Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast. This episode of the podcast features a roundtable discussion of potential deals prior to the JPM Healthcare Conference.

Don’t Miss The Train: Pharma's Future Holds Deeper Digital Deals, Outcome-Based Pacts

Sten Stovall 21 Nov 2017

Asked by Scrip to name two big changes coming pharma's way, Merck KGAA Healthcare CEO Belén Garijo identified artificial intelligence and outcome-based pacts as 'ways of the future'.

Depression drug market

23 Sep 2017

Deep Dive : Depression Drug Development

Inside the payer perspective market

08 Jun 2017

Market Access & Reimbursement: Inside the Payer Perspective on Multiple Myeloma

56 Biosimilars In Late-Stage Development Line Up To Challenge Top Biologic Drugs

18 Apr 2017

Many key biologic drugs, including adalimumab, bevacizumab, rituximab and trastuzumab, are facing biosimilar competition from products that have been either filed or recently approved in Europe.